Beyond the Synapse
Where Brain Healing Begins
NeurANO is developing precision nanotherapeutics that selectively suppress harmful extrasynaptic NMDA receptor signaling while preserving the functions that make the brain work: learning, memory, and recovery.
Target harm
Enable recovery
Preserve function
~ $4M
in Grants from NIA, NINDS, NIDA
Validated in Preclinical Models
Multiple CNS Indications
10 +
Patents / Publications
Independent Validation
Why Traditional NMDAR Blockers Fail?
Cause side effects and have limited efficacy
Off-target effects lead to safety issues and poor clinical outcomes
Small molecules diffuse everywhere
They spread throughout the brain without selectivity
Cannot distinguish synaptic vs extrasynaptic receptors
They lack the precision to target the right receptors at the right place.
Block both beneficial and harmful signaling
They inhibit protective synaptic signaling along with pathological extrasynaptic signaling
Our Approach: Thinking outside the synapse
Large enough to spare synapses
Small enough to reach pathological extrasynaptic receptors
Precision by design
Our Platform
Solving the NMDA paradox with spatial precision
Modular nanotherapeutic design
Spatially selective targeting
One spatially selective eNMDAR platform. Multiple CNS indications.
Alzheimer's Disease
Opioid Use Disorder
Huntington's Disease
Neuroprotection
Enhancing memory
Suppressing inflammation
Reducing amyloid-β burden
Preventing addiction
Easing withdrawal
Reducing craving
Sustaining recovery
Neuroprotection
Restoring motor function
Suppressing inflammation
Reducing mHTT aggregates
Therapeutic Programs Enabled by eNMDAR Targeting
Contact
business@neuranobio.com
Copyright © 2026
All Rights Reserved. All content on this website is protected by copyright law. You may not reproduce or distribute any part of this content without the written permission of NeurANO Bioscience